$2.43.9%upside
Price 6 Months Forecast & Ratings · Updated Sep 11, 2026
45/100 AI Score
Neutral
Brand
25/100
Employment
50/100
User Growth
35/100
Fundamental
63/100
Get INMB AI Score alerts →

INmune Bio (INMB) Price Target: AI vs Analyst Consensus

Our AI model gives INmune Bio (INMB) a 6-month price target of $2.40, representing 3.9% potential upside from the current price of $2.31. The forecast combines financial fundamentals, technical analysis, and 25+ alternative data signals, including hiring trends, web traffic, employee sentiment, and social media activity. INmune Bio’s current AI Score is 45/100 (Neutral).

What’s Driving the INMB Price Target

These are the signals feeding INmune Bio’s AI price target — spanning financial fundamentals, technical analysis, and alternative data — grouped by their recent direction. Improving signals tend to support a higher target; declining signals weigh on it.

Signals trending up

No signals trending up right now.

INMB Stock Forecast for 2026

Our AI model gives INmune Bio (INMB) a 6-month price target of $2.40 — 3.9% upside from the current price of $2.31 — implying a climb toward that level through the rest of 2026. The target updates daily as new INMB financial, technical, and alternative-data signals come in.

INMB Price Prediction for 2027–2030

AltIndex does not publish a multi-year model — alternative data is most predictive over the next 6–12 months. Extending the current trajectory as a simple linear extrapolation projects INMB toward $2.91 by 2030, but long-range estimates carry far more uncertainty and should be treated as directional only. The more reliable signal is whether INmune Bio’s AI Score and the drivers above keep improving over time.

INmune Bio (INMB) Monthly Price Forecast

MonthForecastvs Current
Oct 2026 $2.33 +0.6%
Nov 2026 $2.34 +1.3%
Dec 2026 $2.36 +1.9%
Jan 2027 $2.37 +2.6%
Feb 2027 $2.39 +3.2%
Mar 2027 $2.40 +3.9%

Straight-line projection from the latest price ($2.31) toward our 6-month AI target of $2.40. An estimate, not a month-by-month model.

See how AltIndex’s AI Score picks have performed →

Frequently Asked Questions: INmune Bio Price Prediction

On September 9, INmune Bio (INMB) was assigned a Hold with a target price of $2.40. This signal was predicated on several factors, including a long-term decrease in sentiment across popular stock forums, and a long-term decrease in Twitter followers.
The conviction in the pick is low due to the limited amount of alternative data available.

Based on Alternative Data, INmune Bio is a hold.

Alternative data suggests that it's recommended to approach INmune Bio (INMB) with caution. While there are positive indicators, the overall assessment suggests a hold based on Alternative Data analysis. However, this information should not be considered financial advice.

With an AI score of 45, the INMB stock forecast suggests stability.

To predict the price for INMB in 2027, we can extrapolate the AI price target. This approach projects INMB's price to reach $2.37.

To predict the price for INMB in 2030, we can again extrapolate the AI price target. This approach projects INMB's price to reach $2.91.

When predicting the price for INMB, our approach incorporates multiple scores assessing different aspects of the company. The Brand score measures growth and engagement across social media channels, indicating audience reach. The Employee score evaluates workforce health, considering job postings, business outlook, and employee ratings. The Customer score examines engagement on websites, app downloads, and sentiment in stock forums. Lastly, the Fundamental score analyzes financial statements and analyst ratings. By evaluating this data, we gain a holistic view of the company's performance, enabling more informed price predictions.

Based on technical analysis of how the price has moved over the last 6 months, the likelihood of the price going up tomorrow is 37%. Note that this is a simplistic analysis and should be used with caution, as prices are influenced by a myriad of factors.

Know the moment INmune Bio’s price target changes

Get INMB alerts
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.